Donna R. Vickery

Family Medicine

19 Prospect St
Summit, NJ 07901

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 7 publications

Postimmunotherapy and Vascular Endothelial Growth Factor Inhibitor Landscape in Advanced Renal Cell Carcinoma: Treatment Patterns, Costs, and Outcomes.

Postimmunotherapy and Vascular Endothelial Growth Factor Inhibitor Landscape in Advanced Renal Cell Carcinoma: Treatment Patterns, Costs, and Outcomes.

Journal: JCO oncology practice

Published: October 13, 2025

Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study.

Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study.

Journal: Urologic oncology

Published: August 21, 2025

Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Renal Cell Carcinoma Post-Immune-Oncology and Vascular Endothelial Growth Factor Receptor Targeted Therapies.

Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Renal Cell Carcinoma Post-Immune-Oncology and Vascular Endothelial Growth Factor Receptor Targeted Therapies.

Journal: Cancers

Published: February 07, 2025

Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial.

Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial.

Journal: The Lancet. Oncology

Published: October 09, 2024

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.

Journal: The New England journal of medicine

Published: August 21, 2024

Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.

Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.

Journal: The Lancet. Oncology

Published: August 19, 2024

Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.

Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.

Journal: The Lancet. Oncology

Published: November 29, 2022

Showing 1-7 of 7

Last Updated: 09/26/2026